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Waldenstrom’s macroglobulinaemia is the most commonly reported subtype of lymphoplasmacytic lymphoma (LPL); it is
characterised by IgM secretion. Neurological complications are common usually as a result of hyperviscosity. In rare cases, cells
can infiltrate the central nervous system; this is known as Bing-Neel syndrome. We report the case of a 57-year-old male with
lymphoplasmacytic lymphoma of the IgG-subtypewith neurological symptoms and the consequent finding of lymphoplasmacytoid
cells in his cerebrospinal fluid aswell as deposits onMRI and PET-CT imaging.This is the first report of Bing-Neel syndrome in IgG-
subtype LPL. We discuss the biological and radiological markers of his disease, including PET imaging, which has been minimal
in this area to date.
1. Introduction
Lymphoplasmacytic lymphoma is a small B-cell lymphoma
defined by the WHO as being characterised by clonal B-cells
with plasmacytoid differentiation and secretion of a mon-
oclonal paraprotein, popularly referred to as Waldenstrom’s
macroglobulinaemia when the paraprotein is of the IgM class
[1, 2]. As the majority of cases are IgM secreting, the terms
LPL andWMare often used interchangeably. A small number
of cases are IgG or IgA secreting and these are less well
characterised in the literature.
Neurological complications occur in up to 25%of patients
with LPL [3]. This most commonly presents as stroke or
haemorrhage due to hyperviscosity or peripheral neuropathy
from immunoglobulin deposition. Various pathophysiolog-
ical mechanisms for neuropathy have been described in
WM including limited evidence for antimyelin associated
glycoprotein (anti-MAG) and direct infiltration of the nerves
with IgMparaprotein [4]. However, there is no published data
on non-IgM LPL.
Bing-Neel syndrome (BNS) is described as the presence
of clonal plasmacytoid lymphocytes and plasma cells in the
central nervous system (CNS) with or without cerebrospinal
fluid (CSF) paraprotein and is an extremely rare manifesta-
tion of LPL [5]. Of the fifty or so case reports of BNS in the
literature, all have been a complication of WM. We present
the first recorded case of IgG secreting LPL causing BNS.
2. Case Report
A 57-year-old male presenting with fatigue and a microcytic
anaemia was diagnosed in 2005 with lymphoplasmacytic
lymphoma (LPL) with an immunoglobulin G (IgG) lambda
serum paraprotein of 35 g/L.
In 2006, he received 3 cycles of single agent fludarabine
without response but then achieved a partial response with
combination of fludarabine-cyclophosphamide for a further
4 cycles. This was marked by a fall in his paraprotein from
35 g/L to 11 g/L.
He remained asymptomatic with minimal disease for the
next two years. Bone marrow biopsy performed in January
2010 to investigate a drop in haemoglobin to 10.0 g/dL showed
9% involvement of LPL in the marrow. At this time his serum
IgG concentration was 20 g/L and his B2 microglobulin was
raised at 5.3. By May 2010 his Hb had dropped to 9.1 and
he was feeling progressively more fatigued. CT-PET showed
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Figure 1: CT-PET axial segment showing high uptake in the
paravertebral soft tissue regions at L4/L5.
increased uptake in the cervical, axillary, and external iliac
lymph node chains as well as mild splenomegaly. There was
no significant change on the bone marrow biopsy from the
previous result.
He received 6 cycles of fludarabine, cyclophosphamide,
and rituximab in June 2010 which achieved a complete
metabolic response onCT-PET and resolution of the anaemia
(14.1 g/dL).
He then presented in June 2014 with a 2-month history
of transient visual disturbance, ataxia, and gradual, subtle
cognitive decline. He had been having headaches for 11
months which had been attributed to migraines. He had also
lost 6 kg in the preceding 3 months.
On examination there was no palpable lymphadenopathy
or hepatosplenomegaly.The full blood count was normal and
bone marrow trephine biopsy showed less than 10% infiltra-
tion with B-cell lymphoma. PET/MRI showed metabolically
active soft tissue in the paravertebral region of L4-L5 with
abnormal epidural tissue in L3/L4 and L5/S1 level. There was
moderate metabolic activity at L4 vertebral body.
PET MRI axial fused image [Figure 1], diffuse meningeal
enhancement on coronal MRI brain [Figure 2], and a sagittal
MRI spine demonstrated enhancement of the distal cord and
conus medullaris [Figure 3].
Cerebrospinal fluid (CSF) analysis revealed elevated
oligoclonal IgG and a white cell count of 98 cells per
microlitre.The oligoclonal bands consisted of one prominent
beta 2/fast gamma band and one smaller mid/slow gamma
zone band suggesting a smaller separate clonal population.
CSF cultures grew no bacterial or fungal organisms and
viral PCR was negative. A cytospin preparation of CSF
revealed numerous plasmacytoid cells with some plasma cells
and small lymphocytes [Figure 4]. CSF immunophenotyping
identified a CD5-negative CD23-positive lambda-restricted
B-cell clone, also found in the bone marrow. The IgG
paraprotein level was 1,220 g/L. A diagnosis of LPL stage IV-B
with low level bonemarrow involvement andCNS infiltration
was made. Importantly there were no other sites of disease
and no evidence of transformation to high grade lymphoma.
CNS-directed therapy was instituted with high-dose
intravenous methotrexate; however, after three cycles a lack
of response was documented with unchanged meningeal
enhancement on imaging and presence of clonal B-cells in the
Figure 2: MRI brain coronal view shows diffuse meningeal
enhancement.
Figure 3: MRI lower thoracic and lumbar spine sagittal view show-
ing enhancement of the distal spinal cord and conus medullaris.
Figure 4: Plasmacytoid cells found on cytospin of the cerebrospinal
fluid confirming cellular infiltration of the central nervous system.
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CSF. Therefore, treatment was changed to high-dose cytara-
bine and a complete remission was achieved after two cycles.
In view of the extensive past treatment, plus the difficulty in
clearing theCNSdisease, it was considered that an autologous
peripheral blood stem cell transplant (PBSCT)was warranted
to consolidate the response, although PBSCT is rarely used
for LPL. The PBSCT was performed using BCNU and
Thiotepa chemotherapy for conditioning a regimen used for
primary CNS lymphoma because of its CNS activity.
After transplant there has been mild improvement in the
enhancement pattern in the cord with new areas of very
localised signal abnormality in the subcortical whitematter of
the right posterior temporal lobe and right precentral gyrus
at the vertex without enhancement. These new areas were
thought to be treatment related.
He has had thorough investigation for hyponatraemia
since February 2015, presenting to Accident and Emergency
with headaches, confusion, and a serum sodium concentra-
tion of 123mmol/L. He was treated with low dose hydrocorti-
sone for low cortisol levels and currently has no neurological
symptoms. Sixmonths after transplant he is clinicallywell and
on imaging there is still some abnormal enhancement over
the roots of the cauda equina with patchy but stable signal on
MRI at L4 and S1 indicating low level disease.
3. Discussion
In 1936 Danish physicians Bing and Neel described a triad
of hyperglobulinaemia, neurological symptoms, and pres-
ence of lymphocytes within the central nervous symptoms
[5]. Remarkably this was 8 years before Waldenstrom’s
macroglobulinaemia was defined as a clinical entity [2].
Numerous attempts have been made to categorise Bing-
Neel syndrome.Themost commonly referred to classification
is of “tumoural” and “diffuse” subtypes [6]. Tumoural type
is characterised by focal neurological deficits and seizures
whilst diffuse cases present with headaches, behavioural
change, and decline in cognition. Our patient’s headaches
and slow neurological decline arguably fall under the diffuse
category.
The challenge for the acute physician or general haema-
tologist is to distinguish symptoms caused by hyperviscosity
from direct cellular infiltration. In WM, the IgM paraprotein
level in the blood is closely related to the risks of hyper-
viscosity syndrome [7]; however, there is no relationship
between IgM levels and the risk of BNS. In non-IgM forms
of LPL, the risk of hyperviscosity is considerably lower
and the occurrence of neurological symptoms should evoke
consideration of BNS.
The most commonly reported symptoms of BNS are
headache, ataxia, and progressive cognitive decline [8]. Focal
neurology of the tumoural subtype includes ptosis, facial
droop, and dysarthria.
Blood tests usually show the typical features of LPL
including a normocytic normochromic anaemia, elevated
ESR often >100mm/hour, monoclonal gammopathy on
serum electrophoresis, and occasionally presence of Bence-
Jones protein; however, there are no specific features to
suggest BNS.
Diagnosis ismade on cerebrospinal fluid testing and radi-
ological imaging. Typical CSF findings include an elevated
opening pressure, presence of lymphocytes between 100 and
500mm, and a monoclonal band, although with the IgM
cases there has typically been no link to the amount of protein
in the CSF and presence of BNS or its severity [9]. Cytology
and immunophenotyping of CSF are key inmaking a diagno-
sis: lymphoplasmacytoid cells and mature plasma cells mor-
phologically, with clonal B-cells immunologically (typically,
light chain restricted, CD5-negative B-cells) [10]. MDY88
mutations have a role in differentiating LPL from other B-cell
neoplasms with plasmacytic features but have no association
with neurological infiltration [11]. Our patient was diagnosed
in 2005 before MDY88 became routine in clinical practice.
Whilst CT scanning can detect larger lymphoma nodules
in the tumour form of the disease, most findings are found on
MRI T1 weighted postgadolinium imaging as leptomeningeal
enhancement in the diffuse form [7, 12]. To our knowledge,
this is the first case described in the literature outlining
the findings on PET/CT and PET/MRI. Metabolic imaging
demonstrates extent of disease by showing metabolically
active foci at involved sites and compliments the role of
routine contrast enhanced MRI of the brain by detecting
extracerebral sites of disease.
There are no published guidelines onmanagement of this
condition although a number of regimes have been used.The
most recurrent successful outcomes are associated with the
use of intrathecal methotrexate and purine analogues [6, 9,
13, 14]. Ibrutinib has also been used with success especially on
patients with MYD88 mutations. Little data exists on its use
in either non- IgM LPL or BNS [15]; however, there has been
a recent case report describing successful use of ibrutinib in
IgG LPL suggesting potential for future use in this context
[16].
In our patient, thewidespread FDG-avid lesions through-
out the CNS and his presentation suggested that the LPL was
behaving more like an aggressive lymphoma. Given his age
and good performance status, plus his extensive prior purine
analogue (fludarabine) therapy, he was treated with CNS-
directed high-dose chemotherapy and consolidation with
auto-PBSCT. The use of a primary central nervous system
lymphoma conditioning regime pretransplant has not been
reported before. Its long term success remains to be seen.
Additional Points
This is a unique case to our knowledge and could be classified
as a new entity or a new variant of an existing rare syndrome.
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